Aim: To evaluate micturition disorders and their impact in quality of life in patients with Parkinson disease and parkinsonism. Materials and methods: 70 patients (50 with PD and 20 with P'sm D) submitted to urological evaluation, to uroflow and to a Visual Analog Scale. Results: Only 40 (33 patients with PD and 7 with P'smD) patients reported disuric symptoms secondary to their neuropathy, and according to their urodynamic findings were classified in three groups: A with bladder overactivity, B with bladder weak and C with bladder sphincter dyssinergia. The Qol Vas mean was 7. After 3 months (Time 1) in Group A, there was a complete remission of symptoms in 40%, an improvement in 40% and failure in 20% of patients. The mean of Qol VAS was 4. In group B, 55% patients had got an improvement, 45% did not respond to therapy but the QoL Vas was 6. In group C patients had modest benefits from therapy, 1 patient died for natural causes not correlated with PD. The Qol VAS was 6. At Time 2, after 1 year, in Group A there was a significant reduction of detrusor overactivity, in Group B there was a reduction of incomplete urinary retention of 50% and in Group C, instead, there was not significant change of urodynamic findings. The Qol VAS decreased to 4. Conclusion: The urodynamic findings, different in Parkinson’s disease and Parkinsonism, suggest a target therapy of micturition dysfunctions with an improvement of voiding disorders and in the quality of life.
Aim: To evaluate micturition disorders and their impact in quality of life in patients with Parkinson disease and parkinsonism. Materials and methods: 70 patients (50 with PD and 20 with P'sm D) submitted to urological evaluation, to uroflow and to a Visual Analog Scale. Results: Only 40 (33 patients with PD and 7 with P'smD) patients reported disuric symptoms secondary to their neuropathy, and according to their urodynamic findings were classified in three groups: A with bladder overactivity, B with bladder weak and C with bladder sphincter dyssinergia. The Qol Vas mean was 7. After 3 months (Time 1) in Group A, there was a complete remission of symptoms in 40%, an improvement in 40% and failure in 20% of patients. The mean of Qol VAS was 4. In group B, 55% patients had got an improvement, 45% did not respond to therapy but the QoL Vas was 6. In group C patients had modest benefits from therapy, 1 patient died for natural causes not correlated with PD. The Qol VAS was 6. At Time 2, after 1 year, in Group A there was a significant reduction of detrusor overactivity, in Group B there was a reduction of incomplete urinary retention of 50% and in Group C, instead, there was not significant change of urodynamic findings. The Qol VAS decreased to 4. Conclusion: The urodynamic findings, different in Parkinson’s disease and Parkinsonism, suggest a target therapy of micturition dysfunctions with an improvement of voiding disorders and in the quality of life.
Micturition disorders in Parkinson’s disease and Parkinsonisms
COSTANTINO, Giuseppe;
2012-01-01
Abstract
Aim: To evaluate micturition disorders and their impact in quality of life in patients with Parkinson disease and parkinsonism. Materials and methods: 70 patients (50 with PD and 20 with P'sm D) submitted to urological evaluation, to uroflow and to a Visual Analog Scale. Results: Only 40 (33 patients with PD and 7 with P'smD) patients reported disuric symptoms secondary to their neuropathy, and according to their urodynamic findings were classified in three groups: A with bladder overactivity, B with bladder weak and C with bladder sphincter dyssinergia. The Qol Vas mean was 7. After 3 months (Time 1) in Group A, there was a complete remission of symptoms in 40%, an improvement in 40% and failure in 20% of patients. The mean of Qol VAS was 4. In group B, 55% patients had got an improvement, 45% did not respond to therapy but the QoL Vas was 6. In group C patients had modest benefits from therapy, 1 patient died for natural causes not correlated with PD. The Qol VAS was 6. At Time 2, after 1 year, in Group A there was a significant reduction of detrusor overactivity, in Group B there was a reduction of incomplete urinary retention of 50% and in Group C, instead, there was not significant change of urodynamic findings. The Qol VAS decreased to 4. Conclusion: The urodynamic findings, different in Parkinson’s disease and Parkinsonism, suggest a target therapy of micturition dysfunctions with an improvement of voiding disorders and in the quality of life.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
